Mi az ára Apexigen, Inc. (APGN)

Apexigen, Inc. (APGN) ára $0.385

Mi a Apexigen, Inc. (APGN piaci tőkésítése)

Apexigen, Inc. piaci tőkésítése (APGN) $2.86M

Apexigen, Inc. (APGN) Működési Eredményhányad

Apexigen Inc., established in 2010 and based in San Carlos, California, is a clinical-stage biotechnology company dedicated to the discovery and advancement of antibody-based therapies for oncological diseases. The company's developmental pipeline features several promising candidates. A primary focus is APX005M, a humanized agonist antibody currently in Phase II clinical trials. This therapeutic agent is being explored for its efficacy against a variety of solid tumors, including melanoma, esophageal and gastroesophageal junction cancers, sarcoma, and rectal and ovarian malignancies, often in conjunction with other established treatments like immunotherapy, chemotherapy, radiation therapy, and cancer vaccines. Additionally, Apexigen is progressing APX601, a humanized antagonist antibody, through Phase I/II clinical trials for numerous tumor indications. Rounding out their experimental portfolio is APX801, an NK cell engager engineered to stimulate natural killer cells to eradicate cancerous cells.

Év	Működési árrés	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Működési árrés

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Működési árrés	Működési árrés különbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR
UCB S.A. UCB.BR	31.23%	-	BE

Vállalat

Működési árrés

Működési árrés különbség

Ország